PloS one · 2025
Human umbilical cord-derived mesenchymal stem cells alleviate autoimmune hepatitis by inhibiting hepatic ferroptosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yaqin, Liu Bing, Hu Guoxin, Zhou Tao, He Xuanqiu, Guo Ling, Zhang Luoshi, Tong Weizhao, Chen Yihua, Xu Youhua, Tong Guangdong, Zheng Wei V
Аннотация
BACKGROUND: Autoimmune hepatitis (AIH) is a liver disease marked by immune-mediated hepatocyte damage. Current treatments have variable patient responses and considerable side effects, highlighting the need for alternative therapies. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have shown therapeutic potential in liver diseases, but their mechanisms in AIH remain unclear.
METHODS: A Concanavalin A (ConA)-induced AIH-like mouse model was used to assess the therapeutic effects of hUC-MSCs. Survival, liver function-related serum marker expression, histopathology, and apoptosis were evaluated. Metabolomic profiling and ferroptosis-related markers were analyzed to uncover potential mechanisms.
RESULTS: In ConA-induced AIH-like mouse model challenged with a lethal dose of ConA, hUC-MSC treatment significantly ameliorated liver tissue damage and serum liver function parameters, alleviated hepatocyte apoptosis, and improved survival. Metabolomic and ontology analyses of mouse liver tissue samples revealed that hUC-MSCs treatment altered the levels of metabolites (Glu derivatives and peptides) functionally associated with ferroptosis-related pathways. hUC-MSCs partially reversed ConA-induced malondialdehyde (MDA), oxidized glutathione (GSSG), glutamate, and Fe2+, while restoring reduced glutathione (GSH). Expression of COX2 was downregulated, whereas key ferroptosis suppressors, SLC7A11, GPX4, and FTH1, were upregulated following hUC-MSC treatment.
CONCLUSIONS: Based on the above evidence, we propose that hUC-MSCs may ameliorate ConA-induced liver injury in mice, potentially through modulation of ferroptosis-related pathways, and we support further investigation of hUC-MSCs as potential treatments for AIH. We believe that further in-depth studies are still needed to elaborate on the detailed regulatory mechanisms of MSCs on the ferroptosis pathway during the treatment of AIH.
METHODS: A Concanavalin A (ConA)-induced AIH-like mouse model was used to assess the therapeutic effects of hUC-MSCs. Survival, liver function-related serum marker expression, histopathology, and apoptosis were evaluated. Metabolomic profiling and ferroptosis-related markers were analyzed to uncover potential mechanisms.
RESULTS: In ConA-induced AIH-like mouse model challenged with a lethal dose of ConA, hUC-MSC treatment significantly ameliorated liver tissue damage and serum liver function parameters, alleviated hepatocyte apoptosis, and improved survival. Metabolomic and ontology analyses of mouse liver tissue samples revealed that hUC-MSCs treatment altered the levels of metabolites (Glu derivatives and peptides) functionally associated with ferroptosis-related pathways. hUC-MSCs partially reversed ConA-induced malondialdehyde (MDA), oxidized glutathione (GSSG), glutamate, and Fe2+, while restoring reduced glutathione (GSH). Expression of COX2 was downregulated, whereas key ferroptosis suppressors, SLC7A11, GPX4, and FTH1, were upregulated following hUC-MSC treatment.
CONCLUSIONS: Based on the above evidence, we propose that hUC-MSCs may ameliorate ConA-induced liver injury in mice, potentially through modulation of ferroptosis-related pathways, and we support further investigation of hUC-MSCs as potential treatments for AIH. We believe that further in-depth studies are still needed to elaborate on the detailed regulatory mechanisms of MSCs on the ferroptosis pathway during the treatment of AIH.